23 of 29 patients of CRT group, at least 4 courses of CT were performed to 57% patients. Median overall survival, 1-year survival, and the rate of distant metastases at 1 year were 16 vs 11 (95% CI, 10-13)months, p=0.174; 69% (95% CI, 52%-86%) vs 46% (95% CI, 28%-64%), and 45% vs60%, p=0.301, respectively.
EP-1070
Outcome of gastric lymphoma in elderly patients with reduced dose chemotherapy followed by IFRT. V. Roshan 1 , P. Jagadesan 1 , P. Shukla 1 , P.K. Julka 1 , G.K. Rath 1 1 DRBRAIRCH, All India Institute of Medical Sciences, Radiation Oncology, Delhi, India Purpose/Objective: NHL arises often in extra nodal tissues. Gastrointestinal lymphoma represents the largest group of extra nodal lymphoma. It accounts for approximately 40 percent of them. The most frequent type of non-Hodgkin's lymphoma is diffuse large-B-cell lymphoma. More than half of patients with diffuse large-B-cell lymphoma are over 60 years of age and the treatment of these elderly patients is a difficult challenge. Materials and Methods: This study included 18 patients from 2008 to 2010 of age more than 60 years. All patients were subjected to six cycles of R CHOP followed by involved field radiotherapy. Radiation (45 Gy /25#/5 weeks) was given with linear accelerator(energies used 6, 15 MV) by 3DCRT technique. With Keeping in mind the toxicities associated with these drugs and the KPS of the patient, drug dosage was reduced. In most cases it was reduced by 20-25%. Results: The completion rate of patients with this regimen was 100%. 5 year local control rate was 96%. Five year disease free survival was 74%. Grade III neurotoxicity was seen in one patient.
Conclusions:
The concept of chemotherapy with reduced dosage followed by involved field radiotherapy is safe and effective in managing the Gastric lymphomas even in patients with associated geriatric co morbidities. Purpose/Objective: We are conducting a simultaneous integrated boost (SIB) method using volumetric modulated arc therapy (VMAT)intensity-modulated radiotherapy (IMRT) in preoperative chemoradiation for locally-advanced rectal cancer. We report the initial experience in our department.
EP-1071 SIB method using VMAT-IMRT in preoperative chemoradiation

Materials and Methods:
The object is rectal cancer with invasion to the Rb (rectum below the peritoneal reflection) in stages II-III. It started to register from January, 2012. It is finished in 16 cases up to operative treatment (Total Mesorectal Excision) as of October. In the supine position, 45Gy/25Fr to the whole pelvis and 55Gy/25Fr to the gross tumor volume were given using SIB method of VMAT-IMRT. The combined chemotherapy is multiple drug combination including UFT(tegafur-uracil) + UZEL ± CPT-11. Results: The anal preservation rate was 13/16 case. In the grade by the histologic effect measurement criteria, grade 1 was 8 cases, grade 2 was 2 cases, and grade 3 (= complete response) was 3 cases. The response rate was 47% and it was a good result. The frequency of diarrhea during radiotherapy was low. Conclusions: It is a treatment method tolerated enough. It continues as this regimen.
ELECTRONIC POSTER: CLINICAL TRACK: GENITO-URINARY (PROSTATE INCLUDED)
EP-1072 EBRT after radical prostatectomy in localized prostate cancer: a 5years single-institution experience J. Rodriguez Melcón 1 , M. Federico 1 , L.A. Henriquez Hernandez 1 , D. Macias Verde 2 , E. Ruiz Egea 2 , P.C. Lara Jimenez 1 1 Hospital Dr. Negrin, Radiation Oncology Dpt., Las Palmas de Gran Canaria, Spain 2 Hospital Dr. Negrin, Medical Physics Dpt., Las Palmas de Gran Canaria, Spain Purpose/Objective: To evaluate the series of patients treated with adjuvant-or salvage-External Beam Radiotherapy (EBRT) after radical prostatectomy (RP) in localized prostate cancer, and to revise the derivation criteria from the urology departments. Materials and Methods: A total of 159 patients diagnosed from localized prostate cancer, remitted from 4 different urology departments, were included retrospectively in the study. Patients were treated with radical prostatectomy and posterior EBRT, and were recruited from 2007 to 2012. Clinical and pathological data were colleted, including the risk group (before and after RT), parameters needed for the decision of treatment selection (adjuvant vs. rescue), time to androgen deprivation and dose administered in RT. Response to EBRT in terms of BFFS was also evaluated, defining biochemical failure as PSA level post-EBRT > 0.20 ng/ml. Results: Mean Age: 60.9y (SD: 6.5 EBRT Dose: 66 Gy: 24 (19.74%), 70 Gy: 79 (59,21%), 72-74 Gy: 45 (21,05%), interrupted: 1 (0,63%). After a median-FU of 23 m, 101 patients (63.52%) remains free of biochemical progression, 16 patients (10.06%) have BP and 42 (26.42%) are lost. Perineural invasion pre-RP is a predictor of poor prognosis after post-RP EBRT (p = 0.012). There is a statistically significant benefit in BFFS when RT dose is >72 Gy (p = 0.048), moreover when patients with PD-PSA are analyzed (p = 0.010). The beneficial effect of increased dose is maintained when pre-EBRT PSA is <1 ng/ml (p = 0.008), but not when pre-EBRT PSA is > 1 ng/ml (p = 0.139).
Conclusions:
The majority of patients remitted to our Service for EBRT treatment, followed the criteria established for salvagetreatment. Perineural invasion before RT appeared as a bad prognosis factor. Doses over 72 Gy were associated to longer times to BFFS, especially in those patients with PD-PSA. This effect was observed even when PSE pre.EBRT is < 1 ng/ml, but was not observed when that value was > 1 ng/ml. Purpose/Objective: Single-institution single-arm prospective study. Endpoint: To assess acute toxicity (to exclude >5% of men have grade 3 GU or any grade 3 GI). Materials and Methods: Since 9-2012 seven NCCN intermediate-high prostate cancer patients were treated with helical tomotherapy. Exclusion criteria: Gleason score ≥8, PSA >20, cT3b-4, IPSS≥20, history of acute urinary retention, difficulty following directions.CTsimulation using Combifix™ with empty rectum and 200 ml bladder filled through urine catheter. CTV included prostate and seminal vesicles. PTV margins were 3-10 mm. Total dose to 95% PTV was 45.2 Gy in 8 fx of 5.65 Gy on alternate days. EQD2= 78.2 Gy (a/b3) or 92.3 Gy (a/b1.5). Rectal constraints: V43 <10%, V40 <15%, V37 <20%, V34 <30%, V28 <40%. MVCT for on-line correction in every fraction. Cleansing enema prior each fraction. Bladder volume during irradiation was controlled through: 1) bladder filling using urine catheter (1 st patient), or 2) measuring urine volume right after every fraction to provide feedback about the delay between water intake and treatment. All men received neoadjuvant-concomitant ADT. Results: Patients characteristics are cT1c-3a, Gleason score 6-7, PSA 8-14 ng/ml.,IPSS 5-8. CTCAE acute GI toxicity: 0/7 grade 2, 2/7 grade 1 (rectal discomfort) and 5/7 grade 0. GU figures: 1/7 grade 2 (dysuria), 4/7 grade 1 (frequency,urgency, nocturia) and 2/7 grade 0. GU grade 2 toxicity was related to catheterisation manoeuvres in the first patient, so that dysuria resolved when bladder volume was controlled measuring urine. For the remaining patients the latter procedure was used. In total, after 56 MVCT, the mean and SD corrections in vertical direction were 0.58±2.4 mm (maximum corrections 4±1 mm). Conclusions: Tomotherapy-delivered extreme hypofractionated radiotherapy in selected prostate cancer patients shows promising early results. Our findings suggest that bladder catheterization should be avoided.
EP-1073
EP-1074
EBRT with or without HDR brachytherapy for prostate cancer: salvage treatment for local failure after primary RT. T. Zilli 1 , G. Dipasquale 1 , M. Rouzaud 1 , R. Miralbell 1 1 University Hospital Geneva, Radiation Oncology, Geneva 14, Switzerland Purpose/Objective: The objective of this study was to evaluate the safety, feasibility, side-effect profile, and proof of concept of external beam radiotherapy (EBRT) with or without high-dose-rate brachytherapy (HDR-BT) for salvage of local-only failure after primary EBRT for prostate cancer. Materials and Methods: Fourteen patients (median age=68 years) with local-only recurrence after primary EBRT with or without BT were considered eligible for reirradiation. Median delivered dose in 2 Gyfractions at the first RT (NTD 2Gy , α/β ratio=1.5 Gy) was 74 Gy (66-98.4) using 2D-(n=4) or 3D-conformal RT (n=10). Pelvic RT and a boost with HDR-BT were used in 6 and 2 patients, respectively, with androgen deprivation therapy (ADT) used in 9 (median duration=6 months). At relapse, all patients presented with a local failure-only as documented by prostate biopsies (n=11) and/or radiological imaging including erMRI (n=11) or PET/CT (n=12). Median time between the first RTand the re-irradiation was 6.1 years (range, 4.7-10.2). PSA at re-irradiation ranged between 4.8 and 116 ng/ml (median, 26.7 ng/ml). Gastrointestinal (GI) and genitourinary (GU) toxicity freesurvival and biochemical relapse-free (bRFS), local relapse-free (LRFS), distant metastasis-free (DMFS) and cancer-specific(CSS) survivals were estimated with the Kaplan-Meier method Results: Between 2003 and 2008, a median NTD 2Gy of 85.1 Gy (70-93.4) was delivered as salvage RT to the prostate ± seminal vesicles (SV) with EBRT only (n=4) or EBRT + HDR-BT (n=10), adding ADT in 12 patients (median,12 months). Median delivered dose to the whole prostate ± SV was 45 Gy (44-72), with a boost delivered to the local relapse only, using HDR-BT or IMRT in 10 and 3 patients, respectively. One patient was treated to the whole prostate with 72 Gy in 2.25 Gy per fraction using IMRT. No Grade 3 or more acute GI or GU toxicities were observed during RT or 6-weeks after the end of RT. At a median FU of 70 months (range, 48-121), the 5-yr Grade ≥ 3 GU and GI toxicity-free survival figures were 70±12.4% and 42.9±13.2%, respectively. Three patients presented with combined Grade 4 GU/GI toxicity consisting of rectal-prostatic and/or vesico-rectal fistula formation. One patient presented with rectal necrosis requiring colostomy. Ten and 8 patients presented with biochemical and local relapse, respectively. The 5-yrs bRFS, LRFS, DMFS and CSS were 35.7±12.8%, 50.0±13.4%, 85.7±9.4% and 100%, respectively. Conclusions: EBRT using 3D-CRT and/or IMRT ± HDR BT as salvage option for patients with local recurrence after initial RT for prostate cancer may result in a relatively poor long-term biochemical and local control witha fairly high rate of severe radiation-induced side-effects. Alternative salvage treatment modalities should be first recommended, leaving reirradiation as an exceptional option only to be considered in very carefully selected cases.
EP-1075
Acute anorectal and urinary toxicities in prostate cancer patients treated with IMRT and 3D-CRT T. Akiba 1 , E. Kunieda 1 , R. Nagao 1 , T. Fukuzawa 1 , A. Kogawa 1 , T. Komatsu 1 , Y. Tamai 1 , Y. Oizumi 1 1 Tokai University School of Medicine, Radiation Oncology, Isehara, Japan Purpose/Objective: To compare acute urinary and anorectal toxicities in prostate cancer patients undergoing intensity modulated radiation therapy (IMRT) with those undergoing three dimensional conformal radiation therapy (3D-CRT). Materials and Methods: Between April 2010 and March 2012, 129 consecutive patients who underwent definitive external beam radiation therapy for prostate cancer were evaluated. Patients were retrospectively assigned to two groups: IMRT (N = 53) and 3D-CRT (N = 76). Acute urinary and anorectal toxicities were investigated using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. IMRT was delivered with 74Gy/37 fractions by the 7 field step-andshoot technique; 3DCRT was delivered with 70Gy/35fractions by the static 4-6 multiple field technique. Acute toxicity was defined as the worst event within three months after completing radiation therapy. The two groups' characteristics and treatment factors were compared by t-test and Chi-square or Fisher's exact test, as appropriate. The acute toxicity grades between the groups were compared by Mann-Whitney U-test. Results: Age, National Comprehensive Cancer Network (NCCN) risk groups, and total doses were significantly different between the two groups. There were no grade 3 or higher urinary or anorectal acute toxicities. Although there was no significant difference in urinary acute toxicity, there were significant differences for rectal mucositis (p=0.002) and anal mucositis (p=0.011) for anorectal acute toxicity between the two groups, with milder toxicity in the IMRT group. Conclusions: Acute anorectal toxicity in prostate cancer patients treated with IMRT is significantly milder compared to those treated with 3D-CRT.
EP-1076
Individualized radiotherapy of very high risk prostate cancer with PET and Protons at hands: Learning from two cases I. Turesson 1 , S. Johansson 1 , A. Laurell 1 , L. Åström 1 , K. Nilsson 1 , U. Isaksson 1 , J. Sörensen 2 1 Uppsala University Hospital Akademiska Sjukhuset, Section of Oncology, Uppsala, Sweden
